Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Analyzing the factors that influence occult metastasis in oral tongue cancer

  • Shin, Jung-Hyun (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Yoon, Hye-Jung (Department of Oral Pathology, Dental Research Institute, School of Dentistry, Seoul National University) ;
  • Kim, Soung-Min (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Lee, Jong-Ho (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Myoung, Hoon (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University)
  • Received : 2019.12.12
  • Accepted : 2020.01.28
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: We accessed the various clinico-histopathological factors, and their association with occult metastasis (OM) in oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: One hundred-nine patients with OTSCC were divided into the elective neck dissection (END) group and the watchful waiting (WW) group. Age, sex, T-stage, depth of invasion and differentiation were evaluated to determine the correlation between clinico-histopathological factors and OM. For immunohistochemical analysis, paraffin-embedded blocks of 41 OTSCC specimens were examined with antibodies (VEGF-c, c-Met, and ROR1). Results: The group with tumor thickness of oral tongue cancer ≥3 mm had higher incidence of OM than those with a thickness of <3 mm. The depth of invasion was statistically correlated with OM (P=0.022). Immunohistochemical analysis showed that high expression of VEGF-c (P=0.043), c-Met (P=0.009), and ROR-1 (P=0.003) were statistically correlated with OM. Conclusion: The analysis of these clinico-histopathological and immunohistochemical factors can help to determine neck dissection in clinically negative (cN0) patients.

Keywords

References

  1. Ho CM, Lam KH, Wei WI, Lau SK, Lam LK. Occult lymph node metastasis in small oral tongue cancers. Head Neck 1992;14:359-63. https://doi.org/10.1002/hed.2880140504
  2. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg 1985;8:67-73. https://doi.org/10.1002/hed.2890080202
  3. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci 1982;7:185-92. https://doi.org/10.1111/j.1365-2273.1982.tb01581.x
  4. Whitehurst JO, Droulias CA. Surgical treatment of squamous cell carcinoma of the oral tongue: factors influencing survival. Arch Otolaryngol 1977;103:212-5. https://doi.org/10.1001/archotol.1977.00780210068007
  5. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990;177:379-84. https://doi.org/10.1148/radiology.177.2.2217772
  6. Yuen AP, Wei WI, Wong YM, Tang KC. Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck 1997;19:583-8. https://doi.org/10.1002/(SICI)1097-0347(199710)19:7<583::AID-HED4>3.0.CO;2-3
  7. Werning JW, Heard D, Pagano C, Khuder S. Elective management of the clinically negative neck by otolaryngologists in patients with oral tongue cancer. Arch Otolaryngol Head Neck Surg 2003;129:83-8. https://doi.org/10.1001/archotol.129.1.83
  8. Dunne AA, Folz BJ, Kuropkat C, Werner JA. Extent of surgical intervention in case of N0 neck in head and neck cancer patients: an analysis of data collection of 39 hospitals. Eur Arch Otorhinolaryngol 2004;261:295-303.
  9. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-27. https://doi.org/10.1016/S1535-6108(02)00051-X
  10. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-60. https://doi.org/10.1016/S0002-9440(10)64328-3
  11. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
  12. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61. https://doi.org/10.1016/S1535-6108(03)00085-0
  13. Cao R, Bjorndahl MA, Gallego MI, Chen S, Religa P, Hansen AJ, et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006;107:3531-6. https://doi.org/10.1182/blood-2005-06-2538
  14. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005;24:2885-95. https://doi.org/10.1038/sj.emboj.7600763
  15. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 2014;4:5811. https://doi.org/10.1038/srep05811
  16. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 2008;18:536-44. https://doi.org/10.1016/j.tcb.2008.08.006
  17. Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grander D, et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma 2013;54:843-50. https://doi.org/10.3109/10428194.2012.731599
  18. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 2012;7:e31127. https://doi.org/10.1371/journal.pone.0031127
  19. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012;181:1903-10. https://doi.org/10.1016/j.ajpath.2012.08.024
  20. Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013;73:3649-60. https://doi.org/10.1158/0008-5472.CAN-12-3832
  21. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011;71:3132-41. https://doi.org/10.1158/0008-5472.CAN-10-2662
  22. Faustino SE, Oliveira DT, Nonogaki S, Landman G, Carvalho AL, Kowalski LP. Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2008;37:372-8. https://doi.org/10.1016/j.ijom.2007.11.021
  23. Ma J, Ma J, Meng Q, Zhao ZS, Xu WJ. Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma. Pathol Oncol Res 2013;19:821-32. https://doi.org/10.1007/s12253-013-9650-0
  24. Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck 1999;21:517-25. https://doi.org/10.1002/(SICI)1097-0347(199909)21:6<517::AID-HED4>3.0.CO;2-C
  25. White D, Byers RM. What is the preferred initial method of treatment for squamous carcinoma of the tongue? Am J Surg 1980;140:553-5. https://doi.org/10.1016/0002-9610(80)90210-X
  26. O'Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM. The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg 2000;126:360-5. https://doi.org/10.1001/archotol.126.3.360
  27. Spiro RH, Huvos AG, Wong GY, Spiro JD, Gnecco CA, Strong EW. Predictive value of tumor thickness in squamous carcinoma confined to the tongue and floor of the mouth. Am J Surg 1986;152:345-50. https://doi.org/10.1016/0002-9610(86)90302-8
  28. Brown B, Barnes L, Mazariegos J, Taylor F, Johnson J, Wagner RL. Prognostic factors in mobile tongue and floor of mouth carcinoma. Cancer 1989;64:1195-202. https://doi.org/10.1002/1097-0142(19890915)64:6<1195::AID-CNCR2820640606>3.0.CO;2-7
  29. Mohit-Tabatabai MA, Sobel HJ, Rush BF, Mashberg A. Relation of thickness of floor of mouth stage I and II cancers to regional metastasis. Am J Surg 1986;152:351-3. https://doi.org/10.1016/0002-9610(86)90303-X
  30. Shaha AR, Spiro RH, Shah JP, Strong EW. Squamous carcinoma of the floor of the mouth. Am J Surg 1984;148:455-9. https://doi.org/10.1016/0002-9610(84)90369-6
  31. Franceschi D, Gupta R, Spiro RH, Shah JP. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 1993;166:360-5. https://doi.org/10.1016/S0002-9610(05)80333-2
  32. Umeda M, Yokoo S, Take Y, Omori A, Nakanishi K, Shimada K. Lymph node metastasis in squamous cell carcinoma of the oral cavity: correlation between histologic features and the prevalence of metastasis. Head Neck 1992;14:263-72. https://doi.org/10.1002/hed.2880140402
  33. Frierson HF Jr, Cooper PH. Prognostic factors in squamous cell carcinoma of the lower lip. Hum Pathol 1986;17:346-54. https://doi.org/10.1016/S0046-8177(86)80457-9
  34. Ildstad ST, Bigelow ME, Remensnyder JP. Squamous cell carcinoma of the tongue: a comparison of the anterior two thirds of the tongue with its base. Am J Surg 1983;146:456-61. https://doi.org/10.1016/0002-9610(83)90230-1
  35. Nason RW, Anderson BJ, Gujrathi DS, Abdoh AA, Cooke RC. A retrospective comparison of treatment outcome in the posterior and anterior tongue. Am J Surg 1996;172:665-70. https://doi.org/10.1016/S0002-9610(96)00291-7
  36. Yii NW, Patel SG, Rhys-Evans PH, Breach NM. Management of the N0 neck in early cancer of the oral tongue. Clin Otolaryngol Allied Sci 1999;24:75-9. https://doi.org/10.1046/j.1365-2273.1999.00224.x
  37. Duvvuri U, Simental AA Jr, D'Angelo G, Johnson JT, Ferris RL, Gooding W, et al. Elective neck dissection and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx. Laryngoscope 2004;114:2228-34. https://doi.org/10.1097/01.mlg.0000149464.73080.20
  38. Dias FL, Kligerman J, Matos de Sa G, Arcuri RA, Freitas EQ, Farias T, et al. Elective neck dissection versus observation in stage I squamous cell carcinomas of the tongue and floor of the mouth. Otolaryngol Head Neck Surg 2001;125:23-9. https://doi.org/10.1067/mhn.2001.116188
  39. Hiratsuka H, Miyakawa A, Nakamori K, Kido Y, Sunakawa H, Kohama G. Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer 1997;80:351-6. https://doi.org/10.1002/(SICI)1097-0142(19970801)80:3<351::AID-CNCR1>3.0.CO;2-V
  40. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006;98:1090-3. https://doi.org/10.1111/j.1464-410X.2006.06446.x
  41. Christensen J, Anderes K. Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms. Adv Exp Med Biol 2008;610:43-53. https://doi.org/10.1007/978-0-387-73898-7_4
  42. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103. https://doi.org/10.1038/nrc3205
  43. Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 2000;89:286-92. https://doi.org/10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.0.CO;2-U
  44. Chen YS, Wang JT, Chang YF, Liu BY, Wang YP, Sun A, et al. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004;33:209-17. https://doi.org/10.1111/j.0904-2512.2004.00118.x
  45. Galeazzi E, Olivero M, Gervasio FC, De Stefani A, Valente G, Comoglio PM, et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 1997;254 Suppl 1:S138-43. https://doi.org/10.1007/BF02439745
  46. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 2008;105:3047-52. https://doi.org/10.1073/pnas.0712148105
  47. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012;21:348-61. https://doi.org/10.1016/j.ccr.2012.02.008

Cited by

  1. Depth of invasion versus tumour thickness in early oral tongue squamous cell carcinoma: which measurement is the most practical and predictive of outcome? vol.79, pp.3, 2021, https://doi.org/10.1111/his.14291